You are here: Industry Insights > ARDS

News List

Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19 prnewswire
January 07, 2021
Windtree Therapeutics, Inc. announced that it has dosed the first patient in its Phase 2 clinical trial studying lucinactant in acute lung injury in adults with COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS).
EUSA Pharma launches phase III COVID-19 study for siltuximab pharmatimes
December 18, 2020
UK-headquartered EUSA Pharma has enrolled the first patient in a phase III study of siltuximab in patients hospitalised with COVID-19.
RedHill's COVID-19 Candidate Reduces ARDS-Related Blood Clotting in Preclinical Study americanpharmaceuticalreview
December 16, 2020
RedHill Biopharma announced promising preliminary results from a preclinical study within which opaganib, a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) demonstrating a reduction of thrombosis ...
FDA grants Fast Track designation to COVID-19 ARDS treatment europeanpharmaceuticalreview
December 04, 2020
The designation should expedite the review of remestemcel-L, a cellular therapy that has shown promise in treating acute respiratory distress syndrome (ARDS) in COVID-19 patients.
BioLineRx Initiates ARDS Trial americanpharmaceuticalreview
December 03, 2020
BioLineRx announced the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be evaluated in an investigator-initiated clinical trial in patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19 and ...
Mesoblast signs ARDS therapy development deal with Novartis pharmaceutical-technology
November 25, 2020
Mesoblast and Novartis have signed an exclusive agreement for the development, manufacture and commercialisation of the former’s mesenchymal stromal cell (MSC) product remestemcel-L.
Novartis secures rights to Mesoblast’s remestemcel-L for ARDS pharmatimes
November 23, 2020
Swiss pharma Novartis has inked an exclusive licence and collaboration agreement with Mesoblast to develop remestemcel-L for acute respiratory distress syndrome (ARDS), including COVID-19-associated ARDS.
BioLineRx Announces Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other Respiratory Viral Infections prnewswire
November 19, 2020
BioLineRx Ltd., a clinical-stage biopharmaceutical Company focused on oncology, announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be evaluated in an investigator-initiated clinical trial in patients suffering ...
Stem cell therapy trial for COVID-19 patients with ARDS advised to continue europeanpharmaceuticalreview
November 13, 2020
The trial’s independent Data Safety Monitoring Board (DSMB) recommended that the Phase III study evaluating remestemcel-L continue based on the second interim analysis.
Evgen scores full approval for COVID-19 trial launch pharmatimes
October 28, 2020
Evgen Pharma has received full regulatory approval for its STAR trial, which will investigate the company’s lead asset to treat acute respiratory distress syndrome (ARDS) in patients with suspected COVID-19.

Previous page 1 2 3 4 5 6 7 Next page